CAJ | 학술논문

肺癌是全球范围内癌性死亡的首要因素，发病率、死亡率高，预后较差，急需开发一种新的高效低毒疗法。作为术后辅助或是姑息治疗手段，免疫治疗为非小细胞肺癌患者提供了一个新的治疗方向。免疫疗法作用机理各不相同，如免疫检测点受体抑制剂（抗CTLA4抗体、抗PD-1抗体、抗PD-L1抗体）、主动性免疫疫苗（L-BLP25脂质体疫苗、Belagenpumatucel-L疫苗、MAGE-A3蛋白疫苗）、过继性免疫疫苗（CIK细胞）等，研究表明免疫治疗非小细胞肺癌肿瘤缓解率较前提高，前景值得期待，II期/III期临床试验亦在进一步探索其临床应用价值。本文就当前非小细胞肺癌免疫疗法原理、临床试验、不良反应及待解决问题作一概述。
폐암시전구범위내암성사망적수요인소，발병솔、사망솔고，예후교차，급수개발일충신적고효저독요법。작위술후보조혹시고식치료수단，면역치료위비소세포폐암환자제공료일개신적치료방향。면역요법작용궤리각불상동，여면역검측점수체억제제（항CTLA4항체、항PD-1항체、항PD-L1항체）、주동성면역역묘（L-BLP25지질체역묘、Belagenpumatucel-L역묘、MAGE-A3단백역묘）、과계성면역역묘（CIK세포）등，연구표명면역치료비소세포폐암종류완해솔교전제고，전경치득기대，II기/III기림상시험역재진일보탐색기림상응용개치。본문취당전비소세포폐암면역요법원리、림상시험、불량반응급대해결문제작일개술。
Globally, Lung cancer is the leading cause of cancer-related death of high morbidity and mortality with poor prognosis, which needs some more effective and less toxic therapies. hTe immunotherapies offer a novel approach for the treatment of patients with non-small cell lung cancer (NSCLC) in both the adjuvant and palliative disease settings. A number of promising immunotherapies based on different mechanism have now been evaluated showing an increasing response rate. Moreover, further phase II/III clinical trials will be indicated to explore its value. hTese include checkpoint inhibitors (anti-CT-LA4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody), active vaccination (L-BLP25 liposome vaccine, Belagenpumatucel-L vaccine, MAGE-A3 protein vaccine) and adoptive vaccination (CIK cells). hTe purpose of this paper will draw a summary on the theory, clinical trials, toxicity and problems to be solved of the immunotherapies in NSCLC.